Log In
Print
BCIQ
Print
Print this Print this
 

TTI-1612

  Manage Alerts
Collapse Summary General Information
Company Trillium Therapeutics Inc.
DescriptionRecombinant heparin-binding EGF-like growth factor (HBEGF; DTR) with cytoprotective and anti-inflammatory effects
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase I
Standard IndicationCystitis
Indication DetailsTreat interstitial cystitis/bladder pain syndrome (IC/BPS)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$2.9M

$1.2M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today